Article
Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention.
Frontiers in immunology - 1 Jan 2023
Pan Jing, Xiong Donghai, Zhang Qi, Palen Katie, Shoemaker Robert H, Johnson Bryon, Sei Shizuko, Wang Yian, You Ming
Abstract excerpt
Epidermal growth factor receptor (EGFR) mutations occur in about 50% of lung adenocarcinomas in Asia and about 15% in the US. EGFR mutation-specific inhibitors have been developed and made significant contributions to controlling EGFR mutated non-small cell lung cancer. However, resistance frequently develops within 1 to 2 years due to acquired mutations. No effective approaches that target mutant EGFR have been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.